452 related articles for article (PubMed ID: 26081316)
1. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
3. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
[TBL] [Abstract][Full Text] [Related]
4. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
5. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
[TBL] [Abstract][Full Text] [Related]
6. Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.
Yoshimura K; Harada S; Boonchawalit S; Kawanami Y; Matsushita S
J Gen Virol; 2014 Aug; 95(Pt 8):1816-1826. PubMed ID: 24795449
[TBL] [Abstract][Full Text] [Related]
7. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
Ratcliff AN; Shi W; Arts EJ
J Virol; 2013 Jan; 87(2):923-34. PubMed ID: 23135713
[TBL] [Abstract][Full Text] [Related]
9. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
11. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
12. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
[TBL] [Abstract][Full Text] [Related]
15. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
[TBL] [Abstract][Full Text] [Related]
17. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
[TBL] [Abstract][Full Text] [Related]
18. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
19. CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.
Latinovic O; Reitz M; Le NM; Foulke JS; Fätkenheuer G; Lehmann C; Redfield RR; Heredia A
Virology; 2011 Mar; 411(1):32-40. PubMed ID: 21232779
[TBL] [Abstract][Full Text] [Related]
20. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]